---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027680"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:12:35.391431+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Processa Pharmaceuticals announces 1-for-25 reverse stock split effective Dec 16, 2025

## Summary
- Reverse split reduces outstanding shares 25:1; no change to authorized shares (1B).
- Effective 5:00 p.m. ET Dec 16, 2025; split-adjusted trading begins Dec 17, 2025 under symbol PCSA.
- New CUSIP number 74275C403; fractional shares rounded up to nearest whole share.
- Outstanding options, warrants, and RSUs adjusted proportionally per their terms.
- Stockholders' ownership percentages unchanged except for fractional share rounding.

## SEC filing metadata
- accession: 0001493152-25-027680
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315225027680/0001493152-25-027680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315225027680/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027680
- JSON: https://secwatch.observer/filing/0001493152-25-027680.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027680.txt

## Key facts
- Governance Changes
  Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2025-12-16).
  - Change: charter amendment
  - Effective: 2025-12-16
  source text: On December 12, 2025, Processa Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), effective as of 5:00 p.m. Eastern Time on December 16, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315225027680/0001493152-25-027680-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.